جيآي بي كابيتال CAPITAL

Target Price: SAR50/share Current Price: SAR42.4/share Upside: 18% (+Div. Yield: 2.3%) Rating: Overweight

Arabian International Healthcare (Tibbiyah)

Maintain target price at SAR50/share

- Delays in awarding medical equipment/turnkey business has led to lower than expected revenue in 2022 though 2H22 was inline with historical patterns.
- Further delays will act as overhang while potential from high margin newer business is a key upside driver to profits.
- We value Tibbiyah at 16x P/E and maintain our target price of SAR50/share, implying 18% upside. The stock had rallied 30%+ from October but reversed on profit booking and lower than expected 2022 results.

Business Update: In FY22, the company recorded 3.9% y/y growth in revenue supported by positive contribution from Innovative Healthcare Company (NewYou) and higher demand for medical supplies, partially offset by lower sales volume of medical equipment. The latter continues to be a point of focus with management optimistic of the revenues shifting into 1H23 (forecasted into our model). Gross margin remained broadly stable as expected. However, the bottom line declined by 68.7% to reach SAR26mn due to higher finance charges, higher base and a rise in interest rates as the company secured borrowing to acquire NewYou in 2H22.


New business: Full year impact of NewYou (seen in 2023) will help deliver a 21% revenue growth. Other than that, we factor low single digit growth from core business and a high single digit annualized sales growth from NewYou without factoring in upside from their 50% subsidiary Saudi Advanced Medical Lab, which could contribute more than SAR10mn in net profits from 2024. This could offset any potential delay in the core business. Margins could improve with higher margins for the newer business lines and as the general/admin costs could go lower as there were one off costs relating to the new initiatives and related integration.

Risks: Downside risks to valuation are delayed receivables, interest rate, weaker-than-expected profits of newer investments, and trading illiquidity, given its presence in NOMU. Lack of visibility in the equipment business due to a longer-term shift in market share from public to private healthcare, given its high exposure to Govt. clients, is also a risk factor for the equipment business.

Figure 1	1:	Key financial	metrics
----------	----	---------------	---------

SARmn	2021a	2022a	2023e	2024e
Revenue	619	643	775	811
Revenue growth	-24%	4%	21%	5%
Gross Profit	144	154	194	204
Gross Profit margin	23.2%	24.0%	25.0%	25.1%
EBITDA	114	71	107	115
Net profit	82	26	50	62
Net profit margin	13.3%	4.0%	6.5%	7.6%
EPS (SAR)	4.1	1.3	2.5	3.1
DPS (SAR)	4.1	3.0	1.0	1.9
P/E	10.2x	32.6x	16.8x	13.6x
Source: Company, GIB Capital				

Stock data			
TASI ticker	9530.SE		
Mcap (SARmn)	847		
Avg. Trd. Val (3m) SARmn	0.4		
Free float	25.0%		
QFI holding	0.2%		
NOMUCap Index weight	1.12%		
Source: Bloomberg			
Prices indexed to 100			



Source: Bloomberg

Pritish Devassy, CFA, CPA +966-11-834 8467 Pritish.devassy@gibcapital.com

1

Disclaimer

This research report has been prepared by GIB Capital, Riyadh, Saudi Arabia. It has been prepared for the general use of GIB Capital's clients and may not be altered, redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of GIB Capital. Receipt and review of this research document constitute your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this document prior to public disclosure of such information by GIB Capital. The information contained from various public sources believed to be reliable, but we do not guarantee its accuracy. GIB Capital makes no representations or warranties (express or implied) regarding the data and information provided and GIB Capital does not represent that the information content of this document is complete, or free from any error, not misleading, or fit for any particular purpose. This research document provides general information only. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other investment products related to such securities or investments. It is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person who may receive this document.

Investors should seek financial, legal or tax advice regarding the appropriateness of investing in any securities, other investment or investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities or other investments, if any, may fluctuate and that the price or value of such securities and investments may rise or fall. Fluctuations in exchange rates could have adverse effects on the value of or price of, or income derived from, certain investments. Accordingly, investors may receive back less than originally invested. GIB Capital or its officers (including research analysts) may have a financial interest in securities of the issuer(s) or related investments, including long or short positions in securities, warrants, futures, options, derivatives, or other financial instruments. GIB Capital may from time to time perform investment banking or other services for, solicit investment banking or other business from, any company mentioned in this research document. GIB Capital and employees, shall not be liable for any direct, indirect or consequential loss or damages that may arise, directly or indirectly, from any use of the information contained in this research document. Where the report contains or refers to a recommendation about a specific security or securities service, please note that it may not be suitable for all recipients. Please note that the achievement of any price target may be impeded by general market and economic trends and other external factors, or if a company's profits or operating performance exceed or fall short of our expectations. The subjectivity in future expectations is complex and may miss actual or reported numbers.

This research document and any recommendations contained are subject to change without prior notice. GIB Capital assumes no responsibility to update the information in this research document. This research document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law, or which would subject GIB Capital to any registration or licensing requirement within such jurisdiction

The principal activities of GIB Capital are Dealing, Custody, Managing, Arranging and Advising pursuant to the Capital Market Authority ("CMA") License No. 07078-37.

We use a rating system based on potential upside, 1 year from today, based on our valuation models. For "Overweight" ratings, the estimated upside is >10%, for "Underweight", the estimated downside is <10%. For returns in between +/-10%, we have a Neutral rating.

Contact us for queries:

Pritish Devassy, CFA, CPA Sell Side Research Department, GIB Capital, B1, Granada Business & Residential Park, Eastern Ring Road, PO Box 89589, Riyadh 11692 Pritish.devassy@gibcapital.com | www.gibcapital.com